Family donor care management: Principles and recommendations

Bone Marrow Transplantation

Volumn 45, Issue 8, 2010, Pages 1269-1273

  Van Walraven, S M ^a   Nicoloso De Faveri, G ^b   Axdorph Nygell, U A I ^c   Douglas, K W ^d   Jones, D A ^e   Lee, S J ^f   Pulsipher, M ^g   Ritchie, L ^h   Halter, J ⁱ   Shaw, B E ^h,j  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Swiss Blood Stem Cells   (Switzerland)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d SCOTTISH NATIONAL BLOOD TRANSFUSION SERVICE   (United Kingdom)

^e NHS BLOOD AND TRANSPLANT   (United Kingdom)

^f Fred Hutchinson Cancer Research Center   (United States)

^g UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^h INSTITUTE OF CANCER RESEARCH   (United Kingdom)

ⁱ UNIVERSITY HOSPITAL BASEL   (Switzerland)

^j ANTHONY NOLAN RESEARCH INSTITUTE   (United Kingdom)

more..

Author keywords

donor care management; family donors; stem cell donation; unrelated donors

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR;

ADVERSE OUTCOME; APHERESIS; DONOR; FAMILY ASSESSMENT; FAMILY COUNSELING; FOLLOW UP; HEALTH CARE MANAGEMENT; HEALTH CARE SYSTEM; HEALTH EDUCATION; HLA TYPING; INFORMED CONSENT; MEDICOLEGAL ASPECT; PATIENT COUNSELING; PATIENT RIGHT; PRIORITY JOURNAL; RESEARCH SUBJECT; REVIEW; RISK BENEFIT ANALYSIS; SAFETY; STEM CELL TRANSPLANTATION; TREATMENT DURATION;

BONE MARROW TRANSPLANTATION; FAMILY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INTERNATIONAL AGENCIES; INTERNATIONAL COOPERATION; LIVING DONORS; PRACTICE GUIDELINES AS TOPIC;

EID: 77955577789     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2009.354     Document Type: Review

References (18)

1. Clare S, Mank A, Stone R, Davies M, Potting C, Apperley J, on behalf of the Research Sub-committee of the EBMT Nurses Group and the Late Effects Working party. Management of related donor care: a European survey. Bone Marrow Transplant 2010; 45: 97-101.
2. World Marrow Donor Association International standards for unrelated hematopoietic stem cell donor registries. www. worldmarrow.org/fileadmin/ WorkingGroups-Subcommittees/ Accreditation/Documents/standards-history/WMDA- Standards- December-2007.pdf (accessed 11 April 2009). www.BMDW.org 〈http://www.BMDW.org〉.
3. McGrath P. Identifying support issues of parents of children with leukemia. Cancer Practice 2001; 9: 198-205.
4. Bakken R, Van Walraven AM, Egeland T, for the Ethics Working Group of the World Marrow Donor Association. Donor Commitment and Patient Needs. Bone Marrow Transplant 2004; 33: 225-230.
5. Delany L, Month S, Savulescu J, Browett P, Palmer S. Altruism by proxy: volunteering children for bone marrow donation. Bone Marrow Transplant 1996; 27: 240-243.
6. Clark RE. Bone-marrow donation by mentally incapable adults. Lancet 1998; 352: 1847-1848.
7. van Walraven SM, Heemskerk MBA, Lie JLWT, Barge RMY, Cornelissen JJ, Egeler RM et al. The importance of identifying a back up donor for unrelated stem cell transplantation. Bone Marrow Transplant 2005; 35: 437-440.
8. Rosenmayr A, Hartwell L, Egeland T, on behalf of the Ethics Working Group of the World Marrow Donor Association. Informed consent-suggested procedures for informed consent for unrelated haematopoietic stem cell donors at various stages of recruitment, donor evaluation, and donor work up. Bone Marrow Transplant 2003; 31: 539-545.
9. Directive 2004/23/EC of the European Parliament and of the Council of 31 March 2004 on setting standards of quality and safety for the donation, procurement, testing, processing, preservation, storage and distribution of human tissues and cells.
10. Sacchi N, Costeas P, Hartwell L, Hurley CK, Raffoux C, Rosenmayr A et al, on behalf of the Quality Assurance and Clinical Working Groups of the World Marrow Donor Association. Haematopoietic stem cell donor registries: World Marrow Donor Association recommendations for evaluation of donor health. Bone Marrow Transplant 2008; 42: 9-14.
11. Halter J, Kodera Y, Urbano Ispizua A, Greinix HT, Schmitz N, Favre G et al. For the European Group for Blood and Marrow (EBMT) activity survey office. Severe events in donors after allogeneic hematopoietic stem cell donation. Haematologica 2009; 94: 94-101.
12. Hasenclever D, Sextro M. Safety of AlloPBPCT donors: biometrical considerations on monitoring long term risks. Bone Marrow Transplant 1996; 17(Suppl 2): S28-S30.
13. Nagler A, Korenstein-Ilan A, Amiel A, Avivi L. Granulocyte colony-stimulating factor generates epigenetic and genetic alterations in lymphocytes of normal volunteer donors of stem cells. Exp Hematol 2004; 32: 122-130.
14. Anderlini P, Champlin R. Biologic and molecular effects of granulocyte colony-stimulating factor in healthy individuals: recent findings and current challenges. Blood 2008; 111: 1767-1772.
15. Goldman JM, Madrigal JA, Pamphilon D. Possible harmful effects of short course granulocyte colony-stimulating factor in normal donors. Br J Haematol 2006; 135: 651-652.
16. www.wmda.org.Education/WMDA Forms > Donor follow up forms.
17. Pulsipher MA, Chitphakdithai P, Miller J, Logan BR, King RJ, Rizzo D et al. Adverse events among 2408 unrelated donors of peripheral blood stem cells: results of a prospective trial from the National Marrow Donor Program. Blood 2009; 113: 3604-3611.
18. King R, Confer D, Greinix H, Apperley J, Halter J, Horowitz MM et al., for the Ethics and Clinical Working Groups of WMDA. Unrelated hematopoietic stem cell donors as research subjects (in preparation).